Mantle cell lymphoma – Overview of Information and Clinical Research
The t(11;14)(q13;q32) translocation results in overexpression of cyclin D1 in mantle cell lymphoma.
Mantle cell lymphoma (MCL) is a rare type of non‑Hodgkin B‑cell lymphoma that arises in the mantle zone of lymph nodes. It is characterized by a t(11;14)(q13;q32) translocation leading to cyclin‑D1 overexpression. MCL is usually diagnosed at an advanced stage and is not curable, but a range of therapies – including chemotherapy (e.g., R‑CHOP, Bendamustine‑R), targeted agents (ibrutinib, acalabrutinib, zanubrutinib, Bortezomib), immunotherapy (rituximab), CAR‑T cell therapy, and stem‑cell transplantation – can induce durable remissions. Clinical trials are ongoing to evaluate newer drugs such as pirtobrutinib, Glofitamab, and other combination regimens.
Overexpression of cyclin D1 is a hallmark of mantle cell lymphoma and drives the rapid proliferation of malignant B‑cells, making it a key diagnostic marker and therapeutic target.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa
- Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies
- Mantle Cell Lymphoma
- Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study